Buprenodale multi-dose 0.3 mg.ml solution for injection for dogs, cats and horses

Main information

  • Trade name:
  • Buprenodale multi-dose 0.3 mg.ml solution for injection for dogs, cats and horses
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Buprenodale multi-dose 0.3 mg.ml solution for injection for dogs, cats and horses
    Hungary
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • buprenorphine
  • Therapeutic area:
  • Cats Non Food, Dogs Non Food, Horses Non Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0475/001
  • Authorization date:
  • 31-07-2013
  • EU code:
  • UK/V/0475/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issue:October2013

AN:00696/2012

Page1of7

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

BuprenodaleMultidose,0.3mg/mlsolutionforinjectionfordogs,catsandhorses

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains:

Activesubstance:

Buprenorphine0.3mg

Asbuprenorphinehydrochloride0.324mg

Excipients:

Chlorocresol 1.35mg

Forthefulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Clear,colourlesssolution

4. CLINICALPARTICULARS

4.1Targetspecies

Dogs,catsandhorses.

4.2Indicationsforuse,specifyingthetargetspecies

Post-operativeanalgesiainthedogandcat.

Post-operativeanalgesia,incombinationwithsedation,inthehorse.

Potentiationofthesedativeeffectsofcentrallyactingagentsinthedogandhorse.

4.3Contraindications

Donotadministerbytheintrathecalorperiduralroute.

Donotusepre-operativelyforCaesareansection(seesection4.7).

Donotuseinknowncasesofhypersensitivitytotheactivesubstanceoranyofthe

excipients.

Pleaserefertosection4.11.

4.4Specialwarningsforeachtargetspecies

None.

Issue:October2013

AN:00696/2012

Page2of7

4.5Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Buprenorphinemayoccasionallycauserespiratorydepressionandaswithotheropioid

drugs,careshouldbetakenwhentreatinganimalswithimpairedrespiratoryfunctionor

animalsthatarereceivingdrugsthatcancauserespiratorydepression.

Incaseofrenal,cardiacorhepaticdysfunction,orshock,theremaybegreaterrisk

associatedwiththeuseoftheproduct.Thebenefit:riskratioforusingtheproduct

shouldbemadebytheattendingvet.Safetyhasnotbeenfullyevaluatedinclinically

compromisedcats.

Asbuprenorphineismetabolisedbytheliver,itsintensityanddurationofactionmaybe

affectedinanimalswithimpairedliverfunction.

Thesafetyofbuprenorphinehasnotbeendemonstratedinkittensorpuppieslessthan

7weeksofage,thereforeuseinsuchanimalsshouldbebasedonthebenefit:risk

assessmentoftheveterinarian.

Repeatadministrationearlierthantherecommendedrepeatintervalsuggestedin

Section4.9isnotrecommended.

Long-termsafetyofbuprenorphinehasnotbeeninvestigatedbeyond5consecutive

daysofadministrationincatsor4separateadministrationsonthreeconsecutivedays

inhorses.

Theeffectofanopioidonheadinjuryisdependentonthetypeandseverityoftheinjury

andtherespiratorysupportsupplied.Theproductshouldbeusedinaccordancewiththe

benefit:riskassessmentoftheattendingveterinarian.

Safetyhasnotbeenevaluatedinclinically-compromisedhorses.Inhorses,useof

opioidshasbeenassociatedwithexcitation,buteffectswithbuprenorphineareminimal

whenadministeredinconjunctionwithsedativesandtranquiliserssuchasdetomidine,

romifidine,xylazineandacepromazine.Inhorses,useofbuprenorphinewithouttheprior

useofasedativeagentcancauseexcitementandspontaneouslocomotoractivity.

Ataxiaisaknowneffectofdetomidineandsimilaragents;consequentlyitmaybeseen

afteradministrationofbuprenorphinewithsuchsubstances.Occasionally,ataxiamaybe

marked.Toensureataxichorsessedatedwithdetomidine/buprenorphinedonotlose

theirbalance,theyshouldnotbemovedorotherwisehandledinanywaythatwould

compromisetheirstability.

Buprenorphinemayreducegastrointestinalmotilityinhorses.

Thesafetyofbuprenorphinehasnotbeendemonstratedinhorsesyoungerthan

10monthsoldandweighinglessthan150kg;therefore,useinsuchanimalsshouldbe

basedontherisk:benefitassessmentoftheveterinarian.

ii. Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Asbuprenorphinehasopioid-likeactivity,careshouldbetakentoavoidaccidentalself-

injection.Incaseofaccidentalself-injectionoringestion,seekmedicaladvice

immediatelyandshowthepackageleafletorthelabeltothephysician.

Followingeyecontaminationorskincontact,washthoroughlywithcoldrunningwater.

Seekmedicaladviceifirritationpersists.

Issue:October2013

AN:00696/2012

Page3of7

4.6Adversereactions(frequencyandseriousness)

Salivation,bradycardia,hypothermia,agitation,dehydrationandmiosiscanoccurinthe

dog,andrarelyhypertensionandtachycardia.

Mydriasisandsignsofeuphoria(excessivepurring,pacing,rubbing)commonlyoccurin

catsandwillusuallyresolvewithin24hours.

Buprenorphinemayoccasionallycauserespiratorydepression;refertosection4.5i.

Inhorses,whenusedasdirectedinconjunctionwithsedativesortranquillisers,

excitationisminimalbutataxiamayoccasionallybemarked.Colicisrarelyreported.

4.7Useduringpregnancy,lactationorlay

Pregnancy:

Laboratorystudiesinratshavenotproducedanyevidenceofateratogeniceffect.

However,thesestudieshaveshownpost-implantationlossesandearlyfoetaldeaths.

Thesemayhaveresultedfromareductioninparentalbodyconditionduringgestation

andinpost-natalcareowingtosedationofthemothers.

Asreproductivestudieshavenotbeenconductedinthetargetspecies,useonly

accordingtothebenefit:riskassessmentbytheresponsibleveterinarian.

Theproductshouldnotbeusedpre-operativelyincasesofCaesareansection,dueto

theriskofrespiratorydepressionintheoffspringperiparturiently,andshouldonlybe

usedpost-operativelywithspecialcare(seebelow).

Lactation:

Studiesinlactatingratshaveshownthat,afterintramuscularadministrationof

buprenorphine,concentrationsofunchangedbuprenorphineinthemilkequalledor

exceededthatintheplasma.Asitislikelythatbuprenorphinewillbeexcretedinthemilk

ofotherspecies,useisnotrecommendedduringlactation.Useonlyaccordinglyto

benefit:riskassessmentbytheresponsibleveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Buprenorphinemaycausesomedrowsiness,whichmaybepotentiatedbyother

centrally-actingagents,includingtranquillisers,sedativesandhypnotics.

Thereisevidenceinhumanstoindicatethattherapeuticdosesofbuprenorphinedonot

reducetheanalgesicefficacyofstandarddosesofanopioidagonist,andthatwhen

buprenorphineisemployedwithinthenormaltherapeuticrange,standarddosesof

opioidagonistmaybeadministeredbeforetheeffectsoftheformerhaveendedwithout

compromisinganalgesia.However,itisrecommendedthatbuprenorphineisnotusedin

conjunctionwithmorphineorotheropioid-typeanalgesics,e.g.etorphine,fentanyl,

pethidine,methadone,papaveretumorbutorphanol.

Buprenorphinehasbeenusedwithacepromazine,alphaxalone/alphadalone,atropine,

detomidine,dexmedetomidine,halothane,isoflurane,ketamine,medetomidine,

propofol,romifidine,sevoflurane,thiopentoneandxylazine.

Whenusedincombinationwithsedatives,depressiveeffectsonheartrateand

respirationmaybeaugmented.

4.9Amountstobeadministeredandadministrationroute

Speciesand Post-OperativeAnalgesia Potentiationof

Issue:October2013

AN:00696/2012

Page4of7

route SedativeEffects

Dog:

Intramuscularor

intravenous

injection

10- 20μg/kg(0.3-0.6mlper10kg)

repeatedifnecessaryafter3-4hours

with10μg/kgor5-6hourswith20

μg/kgdoses 10- 20μg/kg

(0.3-0.6mlper10kg)

Cat:Intramuscular

orintravenous

Injection

10- 20μg/kg(0.3-0.6mlper10kg)

repeatedonceifnecessaryafter1 –2

hours --

Horse:

Intravenous

injection

10μg/kg(3.3mlper100kg)5minutes

afteradministrationofanivsedative.

Thedosemayberepeatedonce,if

necessary,afternotlessthan1-2

hours,incombinationwith

intravenoussedation,

5μg/kg(1.7mlper100

kg)5minutesafter

administrationofaniv

sedative,repeatedif

necessaryafter10

minutes.

Whenusedinhorses,anintravenoussedativemustbeadministeredwithinfiveminutes

priortoinjectionofbuprenorphine.

Indogs,sedativeeffectsarepresentby15minutesafteradministration.

Analgesicactivitymaynotdevelopfullyuntil30minutes.Toensurethatanalgesiais

presentduringsurgeryandimmediatelyonrecovery,theproductshouldbe

administeredpreoperativelyaspartofpremedication.

Whenadministeredforpotentiationofsedationoraspartofpremedication,thedoseof

othercentrally-actingagents,suchasacepromazineormedetomidine,shouldbe

reduced.Thereductionwilldependonthedegreeofsedationrequired,theindividual

animal,thetypeofotheragentsincludedinpremedicationandhowanaesthesiaistobe

inducedandmaintained.Itmayalsobepossibletoreducetheamountofinhalational

anaestheticused.

Animalsadministeredopioidspossessingsedativeandanalgesicpropertiesmayshow

variableresponses.Therefore,theresponseofindividualanimalsshouldbemonitored

andsubsequentdosesshouldbeadjustedaccordingly.Insomecases,repeatdoses

mayfailtoprovideadditionalanalgesia.Inthesecases,considerationshouldbegiven

tousingasuitableinjectableNSAID.

Anappropriatelygraduatedsyringemustbeusedtoallowaccuratedosing.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Incasesofoverdosage,supportivemeasuresshouldbeinstituted,and,ifappropriate,

naloxoneorrespiratorystimulantsmaybeused.

Whenadministeredatoverdosetodogs,buprenorphinemaycauselethargy.Atvery

highdoses,bradycardiaandmiosismaybeobserved.

Studiesinhorseswherebuprenorphinehasbeenadministeredwithsedativeshave

shownveryfeweffectsatuptofivetimestherecommendeddosage,butwhen

administeredonitsownitcancauseexcitement.

Issue:October2013

AN:00696/2012

Page5of7

Whenusedtoprovideanalgesiainhorses,sedationisrarelyseen,butmayoccurat

doselevelshigherthanthoserecommended.

Naloxonemaybeofbenefitinreversingreducedrespiratoryrateandrespiratory

stimulantssuchasDoxapramarealsoeffectiveinman.Becauseoftheprolonged

durationofeffectofbuprenorphineincomparisontosuchdrugs,theymayneedtobe

administeredrepeatedlyorbycontinuousinfusion.Volunteerstudiesinmanhave

indicatedthatopiateantagonistsmaynotfullyreversetheeffectsofbuprenorphine.

Intoxicologicalstudiesofbuprenorphinehydrochlorideindogs,biliaryhyperplasiawas

observedafteroraladministrationforoneyearatdoselevelsof3.5mg/kg/dayand

above.Biliaryhyperplasiawasnotobservedfollowingdailyintramuscularinjectionof

doselevelsupto2.5mg/kg/dayfor3months.Thisiswellinexcessofanyclinicaldose

regimeninthedog.

PleasealsorefertoSections4.5and4.6ofthisSPC.

4.11Withdrawalperiod

Theproductisnotauthorisedforuseinhorsesintendedforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Opioids,oripavinederivatives.

ATCVetCode:QN02AE01.

5.1Pharmacodynamicproperties

Insummarybuprenorphineisapotent,long-actinganalgesicactingatopiatereceptors

inthecentralnervoussystem.

Buprenorphinecanpotentiatetheeffectsofothercentrally-actingagents,butunlikemost

opiates,buprenorphinehas,atclinicaldoses,onlyalimitedsedativeeffectofitsown.

Buprenorphineexertsitsanalgesiceffectviahighaffinitybindingtovarioussubclasses

ofopiatereceptors,particularlyµ,inthecentralnervoussystem.Atclinicaldoselevels

foranalgesia,buprenorphinebindstoopiatereceptorswithhighaffinityandhigh

receptoravidity,suchthatitsdissociationfromthereceptorsiteisslow,as

demonstratedininvitrostudies.Thisuniquepropertyofbuprenorphinecouldaccountfor

itslongerdurationofactivitywhencomparedtomorphine.Incircumstanceswhere

excessiveopiateagonistisalreadyboundtoopiatereceptors,buprenorphinecanexert

anarcoticantagonisticactivityasaconsequenceofitshigh-affinityopiatereceptor

binding,suchthatanantagonisticeffectonmorphineequivalenttonaloxonehasbeen

demonstrated.

Buprenorphinehaslittleeffectongastro-intestinalmotility.

5.2Pharmacokineticparticulars

Buprenorphineisrapidlyabsorbedafterintramuscularinjectioninvariousanimal

speciesandman.Thesubstanceishighlylipophilicandthevolumeofdistributionin

bodycompartmentsislarge.

Pharmacologicaleffects(e.g.mydriasis)mayoccurwithinminutesofadministrationand

signsofsedationnormallyappearby15minutes.Analgesiceffectsindogsandcats

appeararound30minuteswithpeakeffectsusuallybeingobservedatabout1 –1.5

Issue:October2013

AN:00696/2012

Page6of7

hours.Inpain-freehorses,antinociceptiveeffectsappearduringthefirst15-30

minutes;peakantinociceptiveeffectsoccurbetween¾and6hoursafteradministration

Followingintravenousadministrationtodogsata20 μg/kgdose,themeanterminalhalf-

lifewas9hoursandthemeanclearancewas24ml/kg/min,however,thereis

considerableinter-dogvariabilityinpharmacokineticparameters.

Followingintramuscularadministrationtocats,themeanterminalhalf-lifewas6.3hours

andtheclearancewas23ml/kg/min;however,therewasconsiderableinter-cat

variabilityinpharmacokineticparameters.

Followingintravenousadministrationinhorses,buprenorphinehasameanresidence

timeofapproximately150minutes,avolumeofdistributionofapproximately2.5l/kg

andaclearancerateof10l/minute.

Combinedpharmacokineticandpharmacodynamicstudieshavedemonstrateda

markedhysteresisbetweenplasmaconcentrationandanalgesiceffect.Plasma

concentrationsofbuprenorphineshouldnotbeusedtoformulateindividualanimal

dosageregimens,whichshouldbedeterminedbymonitoringthepatient’sresponse.

Themajorrouteofexcretioninallspeciesexcepttherabbit(whereurinaryexcretion

predominates)isthefaeces.BuprenorphineundergoesN-dealkylationandglucuronide

conjugationbytheintestinalwallandtheliveranditsmetabolitesareexcretedviathe

bileintothegastro-intestinaltract.

Intissuedistributionstudiescarriedoutinratsandrhesusmonkeysthehighest

concentrationsofdrug-relatedmaterialwereobservedinliver,lungandbrain.Peak

levelsoccurredrapidlyanddeclinedtolowlevelsby24hoursafterdosing.

Proteinbindingstudiesinratshaveshownthatbuprenorphineishighlyboundtoplasma

proteins,principallytoalphaandbetaglobulins.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Chlorocresol

Glucosemonohydrate

Sodiumhydroxide(pHadjustment)

Hydrochloricacid,concentrated(pHadjustment)

Waterforinjection

6.2Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbe

mixedwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years.

Shelf-lifeafterfirstopeningthevial:28days.

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Issue:October2013

AN:00696/2012

Page7of7

6.5Natureandcompositionofimmediatepackaging

Cardboardcartoncontaininga10mlclearTypeIglassvialwithaFluroTeccoated

bromobutylrubberstopperandaluminiumseal.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

DechraLimited

DechraHouse

JamageIndustrialEstate

TalkePits

Stoke-on-Trent

Staffordshire

ST71XW

UK

8. MARKETINGAUTHORISATIONNUMBER

Vm10434/4081

9. DATEOFFIRSTAUTHORISATION

10October2013

10.DATEOFREVISIONOFTHETEXT

October2013

Approved: 10/10/2013

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

There are no news related to this product.